Player FM - Internet Radio Done Right
Checked 7d ago
Menambahkan three tahun yang lalu
Konten disediakan oleh Levine Media Group. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Levine Media Group atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !
Offline dengan aplikasi Player FM !
The Bio Report
Tandai semua (belum/sudah) diputar ...
Manage series 3323646
Konten disediakan oleh Levine Media Group. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Levine Media Group atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
…
continue reading
546 episode
Tandai semua (belum/sudah) diputar ...
Manage series 3323646
Konten disediakan oleh Levine Media Group. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh Levine Media Group atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang diuraikan di sini https://id.player.fm/legal.
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
…
continue reading
546 episode
Semua episode
×T
The Bio Report
1 Take 100 Megabytes a Day and Call Me in the Morning 29:20
29:20
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
29:20Prescription digital therapies, the use of software to treat disease, are growing in number. Already there have been 140 prescription digital therapies that have been granted market access through national regulatory and reimbursement pathways. That represents a five-fold increase in the since 2021, according to the IQVIA Digital Health Trends 2024 report. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about the report, why digital health companies faced challenging times in recent years, and why your next prescription may be in the form of an app.…
T
The Bio Report
1 Extracting the Benefits of Psychedelics 34:25
34:25
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
34:25There has been growing interest in the potential of psychedelics to treat a variety of mental health conditions. While some focus has been put on synthesizing compounds that can target the receptors psychedelics bind to without inducing their hallucinatory effects, Filament Health is taking a notably different approach. The company, co-founded by Ben Lightburn who previously ran a firm specializing in natural extraction technologies, is focusing on developing pharmaceutical grade botanical drugs that may benefit from multiple active compounds rather than an isolated active ingredient. We spoke to Ben Lightburn, founder and CEO of Filament Health, about the company’s approach to psychedelic medicine, the case for natural botanical extracts rather than synthetic compounds, and its lead experimental therapy that targets methamphetamine use disorder.…
T
The Bio Report
1 A Magellan that Circumnavigates Active Binding Sites 37:40
37:40
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
37:40Gain Therapeutics' platform technology Magellan leverages AI, structural biology, and physics-based models to identify novel binding sites on otherwise undruggable proteins implicated in diseases. The company’s experimental Parkinson’s disease therapy has the potential to slow or stop progression of the neurodegenerative condition by stabilizing a lysosomal enzyme implicated in the disease. We spoke to Gene Mack, interim CEO of Gain, about the company’s platform technology, how its experimental therapy for Parkinson’s disease works, and what other conditions might be good candidates for its platform technology to target.…
T
The Bio Report
1 A Very Meh-Ry Biotech Year and What’s Ahead in 2025 40:28
40:28
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
40:28We continue our holiday tradition by welcoming STAT News Senior Biotech Writer Adam Feuerstein for our annual look back at the year that was in biotech and what’s ahead for the industry with the JPMorgan Healthcare conference and beyond in 2025. Feuerstein offers his view on finance and dealmaking in 2024, new drug approvals, and his annual take on the best and worst CEOs of the year. We also discuss what Trump 2.0 may look like for the industry, changes coming to the FDA and other agencies, and what hot technologies to watch in the year ahead.…
T
The Bio Report
1 Using Light to Biomanufacture a Steak 33:43
33:43
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
33:43Prolific Machines uses light to precisely control virtually any function in any cell to transform what is possible with biomanufacturing. In combination with optogenetics and AI, the technology has the potential to impact a wide range of industries, from food production to pharmaceuticals, by enabling new capabilities, reducing costs, and improving sustainability. We spoke to Deniz Kent, co-founder and CEO of Prolific Machines, about the company’s photomolecular platform technology, the benefits it provides over traditional biomanufacturing methods, and how it could be used to not just cultivate meat but make a steak.…
T
The Bio Report
1 Sit, Stay, and Heal: Bringing Precision Medicine to Dogs, then Humans 34:46
34:46
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
34:46ImpriMed is working to deliver on the promise of precision medicine by using a patient’s live cancer cells to see how they respond to different treatment options and artificial intelligence to predict which medicines will work best. The company has had impressive results with its customers to date, but the catch is that it has initially targeted its service to the veterinary market, and its dogs and cats have benefited from it. The company is now working to bring its offering to two-legged patients. We spoke to Sungwon Lim, CEO of ImpriMed, about its functional precision medicine and AI platform to match cancer patients to the best available therapy for them, its decision to roll out the service first to the veterinary market, and what it is doing to bring its service to humans.…
T
The Bio Report
One of the limitations of small molecule drugs and monoclonal antibodies is the difficulty they face in binding to a large number of proteins that could prove to be critical targets in combating various diseases. Aikium is harnessing the power of artificial intelligence and synthetic biology to create a new class of protein biologics called SeqRs that are designed to bind to disordered regions of proteins that have long been beyond the reach of traditional therapeutics. We spoke to Eswar Iyer, co-founder and CEO of Aikium, about the novel class of SeqR proteins the company is developing, how they can bind to targets that traditional medicines can’t, and the potential to transform drug development by expanding the world of druggable targets.…
T
The Bio Report
1 Preventing a Deadly Disease by Detecting It Before It Becomes Cancer 36:44
36:44
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
36:44Esophageal cancer is a growing healthcare concern with a steady increase in the number of cases in the last four decades, a development that runs counter to what’s been seen in other major types of cancer. Some 22,000 people are diagnosed each year in the United States with the disease and it is responsible for 16,000 deaths annually. Now, though, Lishan Aklog, chairman and CEO of Lucid Diagnostics, says today esophageal cancer is preventable through early detection in the pre-cancer stage. We spoke to Aklog about Lucid’s test to detect esophageal cancer, how it works, and its potential to change outcomes for people with the condition by catching it before it turns into a deadly cancer.…
T
The Bio Report
While existing immunotherapies have changed cancer care, there are several types of cancer where they have limited or no efficacy. Pheast Therapeutics is addressing that by looking to macrophages, part of the innate immune system. These white blood cells gobble up pathogens, cancer cells, and other foreign substances. Certain tumors, though, can evade their attack by expressing checkpoints that serve as “don’t eat me” signals. Pheast is developing macrophage checkpoint inhibitors to block these signals and enlist macrophages in the fight against cancers. We spoke to Roy Maute, cofounder and CEO of Pheast Therapeutics, about how tumors evade the innate immune system, the company’s experimental macrophage checkpoint inhibitor, and its initial focus on ovarian and triple negative breast cancer.…
T
The Bio Report
1 Targeting the Dark Matter of the Genome to Treat Diseases 32:33
32:33
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
32:33About 98 percent of the the human genome consists of non-protein coding regions known as the “dark genome.” Once derided as “junk DNA,” these regions are increasingly understood to play a critical role in the regulation of the genome and offer a novel means of targeting diseases. Haya Therapeutics is exploring long non-coding RNAs as potential therapies to treat a range of diseases. We spoke to Samir Ounzain, co-founder and CEO of Haya, about the dark genome, the potential to use lncRNAs to treat diseases, and its recently announced collaboration with Eli Lily to use Haya’s platform technology to discover therapies for obesity and related metabolic conditions…
T
The Bio Report
1 Using AI to Discover Small Molecule Alternatives to Biologics 31:33
31:33
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
31:33One of the promises of AI is to redefine what’s possible by enabling the discovery of compounds that exist in a much larger chemical space than scientists have previously been able to explore. Deepcure is using AI and physics to discover small molecule therapies that can bind to difficult to target proteins. We spoke to Kfir Schreiber, co-founder and CEO of Deepcure, about the company’s AI technology platform, its focus on autoimmune diseases, and why he believes its technology will allow it to develop small molecule drugs that can provide alternatives to biologics to treat these conditions.…
T
The Bio Report
1 A BET on a Novel Approach to Treat Autoimmune Conditions 24:40
24:40
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
24:40The BET family of proteins regulates gene expression. Their overexpression has been implicated in both cancer and inflammatory diseases. Vyne Therapeutics is developing oral and topical BET inhibitors that treat inflammatory conditions ranging from rheumatoid arthritis to the skin condition vitiligo. We spoke to Vyne CEO David Domzalski and Vyne Chief Scientific Officer Iain Stuart, about the role BET plays in autoimmune diseases, its platform technology, and its efforts to develop BET inhibitors that are both potent and specific.…
T
The Bio Report
1 Cell Therapies that Can Do a Solid for People with Cancer 51:49
51:49
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
51:49In August, the U.S. Food and Drug Administration approved Adaptimmune’s Tecelra, the first engineered cell therapy to treat a solid tumor. The T cell receptor gene therapy is approved to treat synovial sarcoma, a rare soft tissue cancer that most often affects young adults. We spoke to Adrian Rawcliffe, CEO of Adaptimmune, about the approval, how TCR therapies differ from CAR T therapies, and what other cancers might benefit from such an approach.…
T
The Bio Report
1 Going to Extremes to Discover New Drugs 31:38
31:38
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
31:38Hibernation is not just a matter of deep sleep. Animals that hibernate are able to do so without suffering damage to tissue and muscle. Understanding the biology of hibernation can unlock potential insights into obesity, heart attack and stroke, muscle atrophy, neuroprotection, and longevity. Fauna Bio is studying genomic data from so-called "extreme mammals" and applying its proprietary AI platform to perform comparative genetic analysis to find gene-disease links and leverage millions of years of evolutionary adaptations to identify new therapeutic opportunities for human health. We spoke to Ashley Zehnder, founder and CEO of Fauna Bio, about the types of insights that can be gleaned from the genetics of hibernating animals, the wide range of human health conditions that might be addressed with such an approach, and the company’s deal with Eli Lilly to apply its AI platform to discover new obesity drugs.…
T
The Bio Report
1 Targeting Senescent Cells to Treat Aging-Related Diseases 31:44
31:44
Putar Nanti
Putar Nanti
Daftar
Suka
Menyukai
31:44Senescent cells, ones that no longer divide but are metabolically active, are associated with aging. They are also implicated in a broad range of aging-related diseases including cancer, diabetes, and neurodegenerative conditions. In the case of cancer, these cells can help protect tumors from a person’s immune system. Immorta Bio is seeking to address aging-related diseases by targeting senescent cells and killing them. We spoke to Thomas Ichim, president and chief scientific officer of Immorta Bio, about aging-related diseases, the role senescent cells play in these conditions, and why the company’s therapeutic approach may also have promise of addressing aging itself and extending healthy years of life.…
Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.